Sardomozide
Alternative Names: CGP 48664; CGP 48664A; SAM 486Latest Information Update: 15 Jun 2009
At a glance
- Originator Novartis
- Class Amidines; Antineoplastics; Indans
- Mechanism of Action Adenosylmethionine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 06 May 2004 A study has been added to the adverse events and Cancer therapeutic trials sections
- 27 Sep 2000 Phase-II clinical trials for Non-Hodgkin's lymphoma in USA (IV-infusion)
- 27 Sep 2000 A phase II study in non-Hodgkin's lymphoma has been added to the therapeutic trials and adverse events sections